When was Causaly founded?

Causaly was founded in 2018 and raised its 1st funding round within a year of its incorporation.

Where is Causaly located?

Causaly is headquartered in London, United Kingdom.

Who is the current CEO of Causaly?

Yiannis Kiachopoulos of Causaly. They have also founded 1 company.

Which legal entities is Causaly associated with?

Causaly is associated with CAUSALY LTD.

How many employees does Causaly have?

As of Jun 30, 2026, the latest employee count at Causaly is 125.

Is Causaly a funded company?

Causaly is a funded company, having raised a total of $93M across 5 funding rounds to date. The company's 1st funding round was a $***** Seed round, raised on Jul 26, 2018.

When was the latest funding round of Causaly?

Causaly's latest funding was a $***** Series B round on Jul 13, 2023, with participation from 8 investors. Its primary sector is Life Sciences Tech. In United Kingdom, the Life Sciences Tech sector has seen $2.24B in funding in 2026 to date.

Where does Causaly rank among its competitors?

Causaly ranks 9th amongst 192 active competitors, of which 70 are funded. It stands 9th in terms of total funding among its competitors. The most recent competitor to raise funding was Isomorphic Labs, which secured $2.1B in May, 2026.

Who are the top competitors of Causaly?

Causaly's top competitors include Schrodinger, Recursion Pharmaceuticals and XtalPi. Among them, Isomorphic Labs secured the most recent funding round in May, 2026.

Causaly - 2026 Company Profile, Team, Funding, Competitors & Financials

Company Details

Provider of an AI platform for life sciences and biomedical research. It helps life sciences and pharmaceutical teams search, visualize, and interpret biomedical knowledge, automate research workflows, and accelerate drug discovery and development. The platform combines knowledge graphs, AI-driven research tools, and workflow automation to improve productivity and decision-making across scientific R&D.

Website: www.causaly.com/
Social
Email ID: *****@causaly.com

Key Metrics

Founded Year

2018

Location

London, United Kingdom

Stage

Series B

Total Funding

$93M in 5 rounds

Latest Funding Round

Series B, Jul 13, 2023, $*****

Investors

Index Ventures & 15 more

Ranked

9^th among 192 active competitors

Employee Count

125 as on Jun 30, 2026

Similar Companies

OpenEvidence & 2518 more

View Causaly's full profile

Causaly is associated with 1 legal entity given below:

Legal Entity Name	Date of Incorporation	Revenue	Latest Employee Count	Documents
CAUSALY LTD CIN: 11368328 , United Kingdom, Active	May 15, 2018	-	72 (As on Dec 31, 2024)

Causaly has raised a total funding of $93M over 5 rounds. Its first funding round was on Jul 26, 2018. Its latest funding round was a Series B round on Jul 13, 2023 for $*****. 8 investors participated in its latest round. Causaly has 9 institutional investors and 7 angel investors.

Here is the list of recent funding rounds of Causaly:

Filter this list

Date of Funding	Funding Amount	Round Name	Post-Money Valuation	Revenue Multiple	Lead Investors	Other Investors
Jul 13, 2023	8467043	Series B	6245414	2794265	3905468	2303255
Oct 24, 2022	4932656	Series A	2515871	1945661	7764490	2145432
May 19, 2021	2397528	Series A	7105261	3990818	Index Ventures	Pentech & 2 more

Access funding benchmarks and valuations. Sign up today!

View details of Causaly's funding rounds and investors

The founders of Causaly is Yiannis Kiachopoulos. Yiannis Kiachopoulos is the CEO of Causaly.

Here are the details of Causaly's key team members:

Yiannis Kiachopoulos: Co-Founder & CEO of Causaly.
Contact Info: 1 email address

Causaly's Board of Directors

Causaly's board has 2 active members. Artur Saudabayev is part of team and Joannis Kiahopoulos is independent board member.

Here is the list of Causaly's board of directors:

Name	Type	Representing	Status	Duration
Artur Saudabayev	Team	-	Current	8y 2m
Joannis Kiahopoulos	Independent board member	-	Current	8y 2m

View details of Causaly's Founder profiles and Board Members

Causaly's employee count trend

Causaly has 125 employees as of Jun 26. Here is Causaly's employee count trend over the years:

Uncover Causaly's growth story! Sign up today!

Access Tracxn on any website

Our Google Chrome extension lets you view company details while browsing their websites

Install Tracxn Extension

Top competitors of Causaly include Schrodinger, Recursion Pharmaceuticals and XtalPi. Here is the list of Top 10 competitors of Causaly, ranked by Tracxn score:

Rank	Company Details	Short Description	Total Funding	Investors	Tracxn Score
1st	Schrodinger 1990, New York City (United States), Acquired	Provider of a web-based simulation and modelling tool	$162M	Gates, WuXi AppTec & 16 others	74/100
2nd	Recursion Pharmaceuticals 2013, New York (United States), Public	AI-enabled drug discovery and development platform for novel therapeutics	$452M	Baillie Gifford, DCVC & 47 others	72/100
3rd	XtalPi 2014, Cambridge (United States), Public	AI-based drug research and development company	$785M	Orbimed, SoftBank Vision Fund & 25 others	67/100
4th	Isomorphic Labs 2021, London (United Kingdom), Series B	Digital platform focused on revolutionizing drug discovery using AI	$2.7B	Thrive Capital, CapitalG & 6 others	64/100
5th	Xaira 2023, San Francisco (United States), Series D	AI-enabled platform for drug discovery and development	$1B	Arch Venture Partners, Foresite Labs & 11 others	63/100
6th	Valo Health 2019, Boston (United States), Series B	AI-powered platform for drug discovery and development	$450M	PSP Investments, Koch Disruptive Technologies ... & 7 others	63/100
7th	Tandem AI 2021, New York (United States), Series A	AI-based drug discovery tool for researchers	$82M	Orbimed, Chengwei Capital & 4 others	62/100
8th	In Silico 2014, Cambridge (United States), Public	AI-enabled bioinformatics platform for drug discovery and biomarker development	$510M	Qiming Venture Partners, Prosperity7 Ventures ... & 36 others	62/100
9th	Causaly 2018, London (United Kingdom), Series B	Provider of an AI platform for life sciences and biomedical research	$93M	Visionaries Club, EBRD & 14 others	62/100
10th	Healx 2014, Cambridge (United Kingdom), Series C	Provider of AI-powered drug discovery solutions for rare diseases	$115M	Atomico, Amadeus Capital & 19 others	62/100